Inverse correlation between RASSF1A hypermethylation, KRAS and BRAF mutations in cervical adenocarcinoma

Gynecologic Oncology

Volumn 105, Issue 3, 2007, Pages 662-666

  Kang, Sokbom ^a   Kim, Hy Sook ^b   Seo, Sang Soo ^a   Park, Sang Yoon ^a   Sidransky, David ^c   Dong, Seung Myung ^a  

^a National Cancer Center   (South Korea)

^b Sungkyunkwan University School of Medicine   (South Korea)

^c JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

BRAF; Cervical adenocarcinoma; KRAS; RASSF1A

Indexed keywords

B RAF KINASE; RAS ASSOCIATION DOMAIN FAMILY PROTEIN 1A;

ADENOCARCINOMA; ADULT; AGED; ARTICLE; CONTROLLED STUDY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN TISSUE; MAJOR CLINICAL STUDY; MUTATIONAL ANALYSIS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN METHYLATION; SEQUENCE ANALYSIS; SQUAMOUS CELL CARCINOMA; UTERINE CERVIX CARCINOMA;

ADENOCARCINOMA; ADULT; AGED; BASE SEQUENCE; CPG ISLANDS; DNA METHYLATION; EPIGENESIS, GENETIC; FEMALE; GENES, RAS; HUMANS; MIDDLE AGED; MOLECULAR SEQUENCE DATA; MUTATION; PROMOTER REGIONS (GENETICS); PROTO-ONCOGENE PROTEINS B-RAF; TUMOR SUPPRESSOR PROTEINS; UTERINE CERVICAL NEOPLASMS;

EID: 34248386122     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2007.01.045     Document Type: Article

References (35)

1. Smith H.O., Tiffany M.F., Qualls C.R., and Key C.R. The rising incidence of adenocarcinoma relative to squamous cell carcinoma of the uterine cervix in the United States-a 24-year population-based study. Gynecol. Oncol. 78 (2000) 97-105
2. Oka K., Nakano T., and Hoshi T. Analysis of response to radiation therapy of patients with cervical adenocarcinoma compared with squamous cell carcinoma. MIB-1 and PC10 labeling indices. Cancer 77 (1996) 2280-2285
3. Eifel P.J., Burke T.W., Morris M., and Smith T.L. Adenocarcinoma as an independent risk factor for disease recurrence in patients with stage IB cervical carcinoma. Gynecol. Oncol. 59 (1995) 38-44
4. Brand E., Berek J.S., and Hacker N.F. Controversies in the management of cervical adenocarcinoma. Obstet. Gynecol. 71 (1988) 261-269
5. Rajagopalan H., Bardelli A., Lengauer C., Kinzler K.W., Vogelstein B., and Velculescu V.E. Tumorigenesis: RAF/RAS oncogenes and mismatch-repair status. Nature 418 (2002) 934
6. Dammann R., Li C., Yoon J.H., Chin P.L., Bates S., and Pfeifer G.P. Epigenetic inactivation of a RAS association domain family protein from the lung tumour suppressor locus 3p21.3. Nat. Genet. 25 (2000) 315-319
7. Vos M.D., Ellis C.A., Bell A., Birrer M.J., and Clark G.J. Ras uses the novel tumor suppressor RASSF1 as an effector to mediate apoptosis. J. Biol. Chem. 275 (2000) 35669-35672
8. Williams J.G., Drugan J.K., Yi G.S., Clark G.J., Der C.J., and Campbell S.L. Elucidation of binding determinants and functional consequences of Ras/Raf-cysteine-rich domain interactions. J. Biol. Chem. 275 (2000) 22172-22179
9. cohen Y., Singer G., Lavie O., Dong S.M., Beller U., and Sidransky D. The RASSF1A tumor suppressor gene is commonly inactivated in adenocarcinoma of the uterine cervix. Clin. Cancer Res. 9 (2003) 2981-2984
10. Kuzmin I., Liu L., Dammann R., Geil L., Stanbridge E.J., Wilczynski S.P., et al. Inactivation of RAS association domain family 1A gene in cervical carcinomas and the role of human papillomavirus infection. Cancer Res. 63 (2003) 1888-1893
11. Yu M.Y., Tong J.H., Chan P.K., Lee T.L., Chan M.W., Chan A.W., et al. Hypermethylation of the tumor suppressor gene RASSFIA and frequent concomitant loss of heterozygosity at 3p21 in cervical cancers. Int. J. Cancer 105 (2003) 204-209
12. Kang S., Kim J.W., Kang G.H., Park N.H., Song Y.S., Kang S.B., et al. Polymorphism in folate- and methionine-metabolizing enzyme and aberrant CpG island hypermethylation in uterine cervical cancer. Gynecol. Oncol. 96 (2005) 173-180
13. van Engel M., Roemen G.M., Brink M., Pachen M.M., Weijenberg M.P., de Bruine A.P., et al. K-ras mutations and RASSF1A promoter methylation in colorectal cancer. Oncogene 21 (2000) 3792-3795
14. Dammann R, Schagdarsurengin U, Liu L, Gimm O, Dralle H, Boehm BO, et al. Frequent RASSF1A promoter hypermethylation and K-ras mutations in pancreatic carcinoma. Oncogene 2003;22:3806-3812, 2003.
15. Xing M., Cohen Y., Mambo E., Tallini G., Udelsman R., Ladenson P.W., et al. Early occurrence of RASSF1A hypermethylation and its mutual exclusion with BRAF mutation in thyroid tumorigenesis. Cancer Res. 64 (2004) 1664-1668
16. Reifenberger J., Knobbe C.B., Sterzinger A.A., Blaschke B., Schulte K.W., Ruzicka T., et al. Frequent alterations of Ras signaling pathway genes in sporadic malignant melanomas. Int. J. Cancer 109 (2004) 377-384
17. Oliveira C., Velho S., Domingo E., Preto A., Hofstra R.M., Hamelin R., et al. Concomitant RASSF1A hypermethylation and KRAS/BRAF mutations occur preferentially in MSI sporadic colorectal cancer. Oncogene 24 (2005) 7630-7634
18. Kang S., Lee J.M., Jeon E.S., Lee S., Kim H., Kim H.S., et al. RASSF1A hypermethylation and its inverse correlation with BRAF and/or KRAS mutations in MSI-associated endometrial carcinoma. Int. J. Cancer 119 (2006) 1316-1321
19. Kang S., Kim J.W., Kang G.H., Lee S., Park N.H., Song Y.S., et al. Comparison of DNA hypermethylation patterns in different types of uterine cancer: cervical squamous cell carcinoma, cervical adenocarcinoma and endometrial adenocarcinoma. Int. J. Cancer 118 (2006) 2168-2171
20. Narayan G., Arias-Pulido H., Nandula S.V., Sugirtharaj D.D., Vargas H., Mansukhani M., et al. Promoter hypermethylation of FANCF: disruption of fanconi anemia-BRCA pathway in cervical cancer. Cancer Res. 64 (2004) 2994-2997
21. Narayan G., Goparaju C., Arias-Pulido H., Kaufmann A.M., Schneider A., Dürst A.M., et al. Promoter hypermethylation-mediated inactivation of multiple Slit-Robo pathway genes in cervical cancer progression. Mol. Cancer 5 (2006) 16
22. Dong S.M., Kim H.S., Rha S.H., and Sidransky D. Promoter hypermethylation of multiple genes in carcinoma of the uterine cervix. Clin. Cancer Res. 7 (2001) 1982-1986
23. Herman J.G., Graff J.R., Myohanen S., Nelkin B.D., and Baylin S.B. Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc. Natl. Acad. Sci. U. S. A. 93 (1996) 9821-9826
24. Lo K.W., Kwong J., Hui A.B., Chan S.Y., To K.F., Chan A.S., et al. High frequency of promoter hypermethylation of RASSF1A in nasopharyngeal carcinoma. Cancer Res. 61 (2001) 3877-3881
25. Davies H., Bignell G.R., Cox C., Stephens P., Edkins S., Clegg S., et al. Mutations of the BRAF gene in human cancer. Nature 417 (2002) 949-954
26. Dong S.M., Traverso G., Johnson C., Geng L., Favis R., Boynton K., et al. Detecting colorectal cancer in stool with the use of multiple genetic targets. J. Natl. Cancer Inst. 93 (2001) 858-865
27. Parker M.F., Arroyo G.F., Geradts J., Sabichi A.L., Park R.C., Taylor R.R., et al. Molecular characterization of adenocarcinoma of the cervix. Gynecol. Oncol. 64 (1997) 242-251
28. Tenti P., Romagnoli S., Silini E., Pellegata N.S., Zappatore R., Spinillo A., et al. Analysis and clinical implications of K-ras gene mutations and infection with human papillomavirus types 16 and 18 in primary adenocarcinoma of the uterine cervix. Int. J. Cancer 64 (1995) 613-619
29. Pappa K.I., Choleza M., Markaki S., Giannikaki E., Kyroudi A., Vlachos G., et al. Consistent absence of BRAF mutations in cervical and endometrial cancer despite KRAS mutation status. Gynecol. Oncol. 100 (2006) 596-600
30. Tannapfel A., Sommerer F., Benicke M., Katalinic, Uhlmann D., Witzigmann H., et al. Mutations of the BRAF gene in cholangiocarcinoma but not in hepatocellular carcinoma. Gut 52 (2003) 706-712
31. Singer G., Oldt R., Cohen Y., Wang B.G., Sidransky A.D., Kurman R.J., et al. Mutations in BRAF and KRAS characterize the development of low-grade ovarian serous carcinoma. J. Natl. Cancer Inst. 95 (2003) 484-486
32. Dellas A., Torhorst J., Gaudenz R., Mihatsch M.J., and Moch H. DNA copy number changes in cervical adenocarcinoma. Clin. Cancer Res. 9 (2003) 2985-2991
33. Narayan G., Arias-Pulido H., Koul S., Vargas H., Zhang F.F., Villella J., et al. Frequent promoter methylation of CDH1, DAPK, RARB, and HIC1 genes in carcinoma of cervix uteri: its relationship to clinical outcome. Mol. Cancer 2 (2003) 24
34. Brunner T.B., Cengel K.A., Hahn S.M., Wu J., Fraker D.L., McKenna W.G., et al. Pancreatic cancer cell radiation survival and prenyltransferase inhibition: the role of K-Ras. Cancer Res. 65 (2005) 8433-8441
35. Dote H., Cerna D., Burgan W.E., Carter D.J., Cerra M.A., Hollingshead M.G., et al. Enhancement of in vitro and in vivo tumor cell radiosensitivity by the DNA methylation inhibitor zebularine. Clin. Cancer Res. 11 (2005) 4571-4579